Skip to main content
Clinical Trials/NCT04209998
NCT04209998
Completed
Not Applicable

New Oxymetry Indices in Critical Limb Ischemia (French Original Title is "Nouveaux Indices Oxymétriques Chez Les Patients Vus Pour Suspicion d'Ischémie Critique du membrE inférieur")

University Hospital, Angers1 site in 1 country300 target enrollmentJanuary 16, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Critical Limb Ischemia
Sponsor
University Hospital, Angers
Enrollment
300
Locations
1
Primary Endpoint
Mortality
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Transcutaneous oxygen tension (TcpO2) at rest, sensitized by oxygen inhalation tests, is widely applied for the evaluation of chronic critical limb ischemia (CLI). If foot TcpO2 measurements are good prognostic factors of the risk of amputation or the probability of wound healing without amputation, they have never proven their hability to estimate the risk of death in patients with critical limb ischemia. On the one hand, studies have considered only the response observed on legs without considered the thoracic variations. On the other hand, the variability of the TcpO2 signal has never been analyzed as a prognostic factor.

The objective of the NOVICE study is therefore to assess, first, whether the variability of resting TcPO2 values at thoracic probe as well as at affected limb probe is a morbidity-mortality prognostic factor and secondly, to evaluate during the oxygen tests, if the measurement of the amplitude of the distal responses in ischemic zone compared to the response observed in thoracic probe is a prognostic factor of morbi-mortality.

Detailed Description

This is an ambispective (both retrospective and prospective) cohort study in which any major patient, referred for resting (transcutyaneous oxygen pressure = TcpO2) for suspicion of critical limb ischemia, is included retrospectively and prospectively from November 2018 to October 2020. Tcpo2 recording are analysed to determine specific parameters (signal variability and response top oxygen). A morbidity-mortality follow-up is carried out between 12 and 15 months after the Tcpo2 measurement. A Kaplan Mayer study of these indices against MALE (major adverse lower limb events ) and MACE(Major adverse cardiovascular events) will be carried out.

Registry
clinicaltrials.gov
Start Date
January 16, 2020
End Date
December 1, 2021
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University Hospital, Angers
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Suspicion of Critical limb ischemia
  • Reffered for Tcpo2 Absence of rebuttal to the use of the data by the patients

Exclusion Criteria

  • No available tcpo2 recording
  • Rejection of the follow up by the patients

Outcomes

Primary Outcomes

Mortality

Time Frame: 12 months

presence of MACE (major adverse cardiovascular event) following the oximetry test

Secondary Outcomes

  • Mortality (intermediate analysis)(6 months minimal follow-up)
  • Morbidity(12 moths)

Study Sites (1)

Loading locations...

Similar Trials